Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
December 01 2017 - 7:00AM
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative and effective
therapeutics for the treatment of cancer, today announced an
upcoming presentation at the 59th American Society of Hematology
(ASH) Annual Meeting and Exposition Dec. 9, 2017, in Atlanta. This
presentation will provide an analysis of results from the Phase 2
trial of CUDC-907.
Date/Time: |
Saturday, Dec. 9, 5:30 p.m. – 7:30 p.m. EST |
Abstract
Number: |
1555 |
Presentation Title: |
Objective
Responses Achieved in Patients with MYC-Altered Relapsed/Refractory
Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC
Inhibitor CUDC-907 |
Location: |
Building A,
Level 1, Hall A2, Georgia World Congress Center, Atlanta |
Additional information on the poster
presentation can be accessed at
https://ash.confex.com/ash/2017/webprogram/Paper104454.html.
About Curis
Curis is a biotechnology company focused on the
development and commercialization of innovative and effective drug
candidates for the treatment of human cancers, including CUDC-907,
which is being investigated in clinical studies in patients with
lymphomas and solid tumors. Curis is also engaged in a broad
collaboration with Aurigene in the areas of immuno-oncology and
precision oncology. As part of this collaboration, Curis has
exclusive licenses to oral small molecule antagonists of the PD1
and VISTA pathways, including PDL1/VISTA antagonist CA-170, and
oral small molecule antagonists of the PD1 and TIM3 pathways,
including PDL1/TIM3 antagonist CA-327, as well as to molecules
designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is
currently undergoing testing in a Phase 1 trial in patients with
advanced solid tumors and lymphomas. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
For More Information:James E.
Dentzer Chief Financial Officer & Chief Administrative
OfficerCuris, Inc. 617-503-6500jdentzer@curis.com
Media ContactDavid SchullRusso
Partners212-845-4271david.schull@russopartnersllc.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024